Novavax INC (NVAX) · 2026-10-30 · Daily technical & news analysis
Novavax INC (NVAX) Technical Analysis — Chart, Levels & News
NVAX Daily Market Briefing and News-Sentiment Read — 2026-10-30
ET · Stocks & ETFs
Information only. This page covers charts, levels, and news for context, not financial or trading advice.
Automated draft. Levels and signals are rules-based and use completed bars.
S&P 500 context: SPY -1.77% on 2026-10-30; this ticker -3.92% in the same completed session.
At a glance
- Trend
- Novavax INC is above its 20-day (11.21), 50-day (10.46), and 200-day (9.29) averages. The trend reads up.
- Key levels
- Nearest support is 9.84 (-2.23% below). Nearest resistance is 10.46 (+3.97% above).
- Risk snapshot
- A typical day has moved about +8.92%% recently.
- Support below
- 9.84 | 9.67 | 9.29
- Resistance above
- 10.46 | 10.99 | 11.21
What changed since the last close
- Closed below the 50-day average
Signal — short-term technical (daily chart)
On the short-term daily chart horizon, NVAX displays a bearish bias characterized by negative momentum and a close below the short-term moving averages. Conviction remains moderate given conflicting fundamental news flow. No candlestick pattern was detected on the latest completed bar, meaning price action lacks a formal timing signal at this juncture.
News, Macro & Industry Context
The medium-term narrative tone is bullish. Novavax announced that Sanofi dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in Europe, triggering a $125 million milestone payment for Novavax. Additionally, the company announced it will report its third quarter 2026 financial results before the open of the U.S. financial markets on November 5, 2026, accompanied by a conference call. Sector backdrop remains dynamic within healthcare as broader equity indices navigate volatility and sector rotation. Broader market commentary highlights ongoing risk awareness and technical testing across key equity indices, reflecting a cautious macro environment as investors weigh upcoming data prints and corporate earnings.
Catalysts
Upcoming catalysts include the third quarter 2026 financial results release and conference call scheduled for November 5, 2026, alongside ongoing updates from the Sanofi partnership and combination vaccine trial.
Levels & Risk
Key support levels are identified at the volume point of control, value area low, and the value area high for overhead resistance. Fair value gap zones serve as additional structural reference points below and above current price action. Invalidation of the current bounce setup occurs upon sustained acceptance below lower value bounds. Risk is managed against the lower FVG supports and structural volume nodes.
Technical Breakdown
- WaveTrend: bearish momentum (fast below slow), mid-range
- SMI: bullish (above signal), mid-range
- Trend: price below EMA20 (downtrend bias); EMA5 below EMA13 (short-term bearish)
- Triggers: no fresh trigger bars
- Candlestick pattern: none detected on the latest completed bar
- Higher timeframe: no higher-timeframe extreme
Learn the chart
Start with the question you have, not a trading strategy. Each guide explains one part of a ticker page in plain language.
Educational technical analysis. Not financial advice. Market data may be delayed or incomplete.